Role of Volatile Anesthetics for Hepatic Protection

Reperfusion Injury Clinical Trial

Official title:

Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00516711
• Other study ID #: StV 5-2006
• Status: Completed
• Phase: N/A
• First received: August 14, 2007
• Last updated: September 14, 2010
• Start date: March 2006
• Est. completion date: December 2007

Study information

• Verified date: August 2007
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the attenuation of ischemic-reperfusion injury in the liver after sevoflurane preconditioning. In the presence of sevoflurane, an attenuation of liver injury is hypothesized (diminished increase of liver enzymes, reduced production of inflammatory mediators).

Description:

Organ protection; preconditioning; volatile anesthetics; ischemia reperfusion

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: December 2007
• Est. primary completion date: December 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Older than 18 years of age

• Patients undergoing liver resection (benign or malignant tumors)

Exclusion Criteria:

• Laparoscopic liver resection coagulopathy (platelets < 50,000/ml, Quick < 50%)

• Liver cirrhosis

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Reperfusion Injury

Intervention

Drug:
• Sevoflurane

Locations

Country	Name	City	State
Switzerland	University Hospital of Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT)